Harrow, Inc., a leading player in the pharmaceutical industry, is headquartered in the United States and operates primarily in the specialty pharmaceuticals sector. Founded in 2013, the company has made significant strides in developing innovative treatments, particularly in the areas of ophthalmology and other niche therapeutic markets. Harrow's core offerings include a range of proprietary prescription eye medications, distinguished by their unique formulations and delivery methods. The company has established a strong market position, recognised for its commitment to improving patient outcomes through advanced drug development. With a focus on quality and efficacy, Harrow continues to achieve notable milestones, solidifying its reputation as a trusted name in specialty pharmaceuticals.
How does Harrow, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Harrow, Inc.'s score of 25 is lower than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Harrow, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as there are no available figures for kg CO2e emissions. Additionally, the company has not established any documented reduction targets or climate pledges. As a result, there is no information on their Scope 1, 2, or 3 emissions, nor any significant achievements in carbon reduction initiatives. The absence of emissions data and climate commitments suggests that Harrow, Inc. may still be in the early stages of developing a comprehensive sustainability strategy. In the context of industry standards, it is essential for companies to set measurable targets and report emissions transparently to align with global climate goals. Without such commitments, Harrow, Inc. may face challenges in demonstrating its dedication to addressing climate change and reducing its carbon footprint.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Harrow, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
